Inhalable Biologics Drug Delivery Market
完整報告名稱與涵蓋範圍
Inhalable Biologics Drug Delivery Market Size, Share & Trends Analysis Report, By Molecule Type (Inhaled Monoclonal Antibodies and Fragments, Inhaled Proteins, Peptides and Enzymes, Inhaled Nucleic Acid and Gene Therapies, Inhaled Vaccines), By Delivery Technology (Dry Powder Inhalers, Nebulizers and Soft Mist Inhalers, Novel Aerosol and Vibrating Mesh Platforms), By Indication (Respiratory Infections and Prophylaxis, Asthma and COPD, Cystic Fibrosis and Rare Lung Diseases, Systemic Delivery via the Lung), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The inhalable biologics drug delivery market covers biologic medicines delivered to or through the lung, including inhaled antibodies and antibody fragments, proteins, peptides and enzymes, nucleic acid and gene therapies and mucosal vaccines, together with the dry powder, nebulizer and novel aerosol technologies and formulation services that enable them. Inhaled small-molecule bronchodilators and corticosteroids are excluded, as are injectable biologics for respiratory disease.
Interest is driven by the ability to place high local concentrations of biologics at the site of lung disease while limiting systemic exposure, by patient preference for non-injectable options in chronic respiratory conditions and by pandemic-era work on inhaled antibodies and mucosal vaccines. Commercial products include inhaled insulin, inhaled granulocyte-macrophage colony-stimulating factor and inhaled DNase, while the pipeline spans inhaled antibody fragments for asthma, inhaled mRNA and gene therapies for cystic fibrosis and inhaled anti-infective biologics. Formulation stability, aerosol performance of large molecules, device-drug combination regulation and manufacturing of powders and vesicles are the principal technical barriers.
North America and Europe lead development and device supply, with Japan and China increasing activity. Competition combines aerosol device makers, inhalation formulation CDMOs, respiratory pharmaceutical franchises and RNA delivery companies targeting the lung.
The InsightAce study supplies US$ forecasts for all molecule type, delivery technology, indication and end user and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Inhalable Biologics Drug Delivery Market Snapshot
Chapter 4. Global Inhalable Biologics Drug Delivery Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Molecule Type Estimates & Trend Analysis
5.1. Molecule Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Molecule Type:
5.2.1. Inhaled Monoclonal Antibodies and Fragments
5.2.2. Inhaled Proteins, Peptides and Enzymes
5.2.3. Inhaled Nucleic Acid and Gene Therapies
5.2.4. Inhaled Vaccines
Chapter 6. Market Segmentation 2: By Delivery Technology Estimates & Trend Analysis
6.1. Delivery Technology & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Delivery Technology:
6.2.1. Dry Powder Inhalers
6.2.2. Nebulizers and Soft Mist Inhalers
6.2.3. Novel Aerosol and Vibrating Mesh Platforms
Chapter 7. Market Segmentation 3: By Indication Estimates & Trend Analysis
7.1. Indication & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
7.2.1. Respiratory Infections and Prophylaxis
7.2.2. Asthma and COPD
7.2.3. Cystic Fibrosis and Rare Lung Diseases
7.2.4. Systemic Delivery via the Lung
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Hospitals
8.2.2. Home and Self-Administration
8.2.3. Clinical Research Sponsors
Chapter 9. Inhalable Biologics Drug Delivery Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Aerogen Ltd.
11.2. PARI GmbH
11.3. Philips (Respironics)
11.4. Vectura Group (Philip Morris International)
11.5. Catalent (Novo Nordisk A/S)
11.6. MannKind Corporation
11.7. Savara Inc.
11.8. Insmed Incorporated
11.9. Ethris GmbH
11.10. ReCode Therapeutics, Inc.
11.11. Areteia Therapeutics, Inc.
11.12. AstraZeneca plc
11.13. Aptar Pharma
11.14. Boehringer Ingelheim International GmbH
11.15. Nanopharm (Aptar)
圖表清單 List of Tables & Figures
Table 1. Global Inhalable Biologics Drug Delivery Revenue Forecast by Molecule Type, 2026-2035 (US$ Mn)
Figure 1. Global Inhalable Biologics Drug Delivery Market Snapshot, 2026 & 2035
Table 2. Global Inhalable Biologics Drug Delivery Revenue Forecast by Delivery Technology, 2026-2035 (US$ Mn)
Figure 2. Global Inhalable Biologics Drug Delivery Market Share by Delivery Technology, 2026 & 2035
Table 3. Global Inhalable Biologics Drug Delivery Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 3. Inhalable Biologic Products and Pipeline by Molecule Type and Delivery Technology
Table 4. Global Inhalable Biologics Drug Delivery Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Aerosol Performance and Stability Challenges for Large-Molecule Inhalation
Table 5. North America Inhalable Biologics Drug Delivery Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Inhalable Biologics Drug Delivery Growth Opportunity Analysis
Table 6. Europe Inhalable Biologics Drug Delivery Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Device-Drug Combination Regulatory Pathway for Inhaled Biologics
Table 7. Asia Pacific Inhalable Biologics Drug Delivery Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Inhalable Biologics Drug Delivery Market Participants
Table 8. Latin America and Middle East & Africa Inhalable Biologics Drug Delivery Revenue Forecast, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們